Literature DB >> 31153519

γ-herpesvirus latency attenuates Mycobacterium tuberculosis infection in mice.

Halli E Miller1, Kaitlin E Johnson1, Vera L Tarakanova2, Richard T Robinson3.   

Abstract

Tuberculosis is caused by Mycobacterium tuberculosis (Mtb), a bacterial pathogen which is transmitted via aerosol and establishes a chronic lung infection. In naïve hosts, Mtb grows for several weeks without being restricted by IFNγ-producing T cells, which eventually accumulate and limit Mtb dissemination. In this study, we used a mouse model of Mtb/γ-herpesvirus (γHV) coinfection to test the hypothesis that latent γHV infection alters host resistance to Mtb. γHVs are DNA viruses which elicit a polyclonal T cell response and attenuate some acute bacterial pathogens in mice; whether γHVs modulate infection with Mtb is unknown. Here, mice harboring latent mouse gammaherpesvirus 68 (MHV68)-a γHV genetically and biologically related to human Epstein Barr virus (EBV)-were infected via aerosol with a low dose of virulent Mtb. Mtb burdens and IFNγ+ T cell frequencies in mice with latent MHV68 (MHV68POS mice) were subsequently measured and compared to control mice that did not harbor latent MHV68 (MHV68NEG mice). Relative to MHV68NEG controls, MHV68POS mice more effectively limited Mtb growth and dissemination, and had higher frequencies of CD4+IFNγ+ cells in lung-draining lymph nodes. Collectively, our results support a model wherein latent γHV confers moderate protection against subsequent Mtb infection.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Year:  2019        PMID: 31153519      PMCID: PMC6876742          DOI: 10.1016/j.tube.2019.04.022

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  45 in total

1.  Primary Epstein-Barr virus infections in African infants. I. Decline of maternal antibodies and time of infection.

Authors:  R J Biggar; W Henle; G Fleisher; J Böcker; E T Lennette; G Henle
Journal:  Int J Cancer       Date:  1978-09-15       Impact factor: 7.396

2.  gamma-Herpesvirus-induced protection against bacterial infection is transient.

Authors:  Eric J Yager; Frank M Szaba; Larry W Kummer; Kathleen G Lanzer; Claire E Burkum; Stephen T Smiley; Marcia A Blackman
Journal:  Viral Immunol       Date:  2009-02       Impact factor: 2.257

Review 3.  Redefining chronic viral infection.

Authors:  Herbert W Virgin; E John Wherry; Rafi Ahmed
Journal:  Cell       Date:  2009-07-10       Impact factor: 41.582

4.  B Cell-Specific Expression of Ataxia-Telangiectasia Mutated Protein Kinase Promotes Chronic Gammaherpesvirus Infection.

Authors:  Eric J Darrah; Joseph M Kulinski; Wadzanai P Mboko; Gang Xin; Laurent P Malherbe; Stephen B Gauld; Weiguo Cui; Vera L Tarakanova
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

5.  Early control of Mycobacterium tuberculosis infection requires il12rb1 expression by rag1-dependent lineages.

Authors:  Halli E Miller; Richard T Robinson
Journal:  Infect Immun       Date:  2012-08-20       Impact factor: 3.441

6.  Non-antigen-specific B-cell activation following murine gammaherpesvirus infection is CD4 independent in vitro but CD4 dependent in vivo.

Authors:  P G Stevenson; P C Doherty
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

7.  Infection of neonates with murine gammaherpesvirus 68 results in enhanced viral persistence in lungs and absence of infectious mononucleosis syndrome.

Authors:  Catherine Ptaschinski; Rosemary Rochford
Journal:  J Gen Virol       Date:  2008-05       Impact factor: 3.891

Review 8.  The End of the Binary Era: Revisiting the Spectrum of Tuberculosis.

Authors:  Philana Ling Lin; JoAnne L Flynn
Journal:  J Immunol       Date:  2018-11-01       Impact factor: 5.422

9.  Seroprevalence of Epstein-Barr virus infection in U.S. children ages 6-19, 2003-2010.

Authors:  Jennifer Beam Dowd; Tia Palermo; Jennifer Brite; Thomas W McDade; Allison Aiello
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

10.  Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.

Authors:  Michele D Tameris; Mark Hatherill; Bernard S Landry; Thomas J Scriba; Margaret Ann Snowden; Stephen Lockhart; Jacqueline E Shea; J Bruce McClain; Gregory D Hussey; Willem A Hanekom; Hassan Mahomed; Helen McShane
Journal:  Lancet       Date:  2013-03-23       Impact factor: 79.321

View more
  3 in total

Review 1.  The Many Hosts of Mycobacteria 8 (MHM8): A conference report.

Authors:  Michelle H Larsen; Karen Lacourciere; Tina M Parker; Alison Kraigsley; Jacqueline M Achkar; Linda B Adams; Kathryn M Dupnik; Luanne Hall-Stoodley; Travis Hartman; Carly Kanipe; Sherry L Kurtz; Michele A Miller; Liliana C M Salvador; John S Spencer; Richard T Robinson
Journal:  Tuberculosis (Edinb)       Date:  2020-02-11       Impact factor: 3.131

2.  Elevated IL-35 level and iTr35 subset increase the bacterial burden and lung lesions in Mycobacterium tuberculosis-infected mice.

Authors:  Fangliu Yu; Xinying Zhu; Qingdeng Li; Wenqin Xu; Yunxing Gao; Yufeng Wen; Qiong Zhang; Jun Dou
Journal:  Open Life Sci       Date:  2022-03-31       Impact factor: 0.938

3.  Conquering the Host: Determinants of Pathogenesis Learned from Murine Gammaherpesvirus 68.

Authors:  Yiping Wang; Scott A Tibbetts; Laurie T Krug
Journal:  Annu Rev Virol       Date:  2021-09-29       Impact factor: 14.263

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.